Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection

NCT04590547 is registered in ClinicalTrials.gov with GeneOne Life Science, Inc. as lead sponsor.

NCT NCT04590547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04590547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection
Lead sponsor
GeneOne Life Science, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 7, 2021
Completion date
July 24, 2023
Enrollment
132 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

pneumonitis, sars-cov infection